Intech Investment Management LLC cut its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 75.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,230 shares of the biopharmaceutical company’s stock after selling 106,048 shares during the period. Intech Investment Management LLC’s holdings in Incyte were worth $4,275,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in INCY. Hantz Financial Services Inc. raised its stake in shares of Incyte by 6.8% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,446 shares of the biopharmaceutical company’s stock worth $175,000 after buying an additional 92 shares during the period. Ground Swell Capital LLC acquired a new stake in Incyte in the 3rd quarter valued at $564,000. Bellwether Advisors LLC acquired a new stake in Incyte in the 3rd quarter valued at $1,201,000. Phoenix Financial Ltd. purchased a new stake in Incyte in the 3rd quarter worth $247,000. Finally, Danske Bank A S increased its holdings in Incyte by 84.4% in the 3rd quarter. Danske Bank A S now owns 150,974 shares of the biopharmaceutical company’s stock worth $18,321,000 after acquiring an additional 69,112 shares in the last quarter. 96.97% of the stock is owned by institutional investors and hedge funds.
Incyte Stock Performance
Shares of INCY opened at $117.80 on Thursday. Incyte Corporation has a one year low of $89.25 and a one year high of $132.60. The stock has a market capitalization of $24.01 billion, a price-to-earnings ratio of 62.66, a PEG ratio of 4.24 and a beta of 0.78. The stock has a 50 day moving average price of $118.78 and a 200 day moving average price of $109.23.
Incyte (NASDAQ:INCY – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.93) by $0.33. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The company had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.46 billion. During the same quarter last year, the firm posted $2.26 EPS. The firm’s revenue for the quarter was up 14.0% on a year-over-year basis. On average, analysts predict that Incyte Corporation will post 2.29 earnings per share for the current year.
More Incyte News
Here’s some of the latest news about INCY:
- Positive Sentiment: The European Commission approved Povofortay (povorcitinib) as the first once-daily oral treatment for adults with moderate-to-severe hidradenitis suppurativa (HS) in Europe. Approval opens a new commercial opportunity, though the reports provide no sales forecast or launch details. Incyte approval announcement
- Positive Sentiment: Piper Sandler maintained its Buy rating on Incyte, signaling continued analyst confidence, although the provided report does not include a revised price target or new rationale. Piper Sandler rating report
- Neutral Sentiment: EVP Lee Heeson sold 10,694 shares worth about $1.29 million, reducing his direct holdings by 28.46%. The trade was made under a pre-arranged Rule 10b5-1 plan, making it a less definitive signal about his outlook for Incyte. Insider sale report
Insider Buying and Selling at Incyte
In other news, insider Pablo Cagnoni sold 2,642 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $112.71, for a total value of $297,779.82. Following the completion of the sale, the insider directly owned 183,200 shares in the company, valued at $20,648,472. This represents a 1.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Lee Heeson sold 10,694 shares of the stock in a transaction dated Friday, November 13th. The shares were sold at an average price of $120.82, for a total transaction of $1,292,049.08. Following the completion of the sale, the executive vice president owned 26,884 shares of the company’s stock, valued at $3,248,124.88. This trade represents a 28.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 254,139 shares of company stock worth $30,098,844 over the last three months. 16.20% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
INCY has been the subject of a number of research analyst reports. Truist Financial upped their price objective on shares of Incyte from $105.00 to $115.00 and gave the stock a “hold” rating in a research report on Wednesday, October 14th. Stifel Nicolaus lifted their target price on shares of Incyte from $145.00 to $157.00 and gave the company a “buy” rating in a research report on Monday, October 5th. Guggenheim boosted their target price on shares of Incyte from $136.00 to $150.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Jefferies Financial Group set a $115.00 target price on shares of Incyte and gave the stock a “hold” rating in a research note on Tuesday. Finally, Sanford C. Bernstein upped their price target on shares of Incyte from $104.00 to $108.00 and gave the stock a “market perform” rating in a research report on Monday, November 2nd. Eleven investment analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $133.86.
Read Our Latest Analysis on INCY
Incyte Profile
Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.
Featured Articles
- Five stocks we like better than Incyte
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY – Free Report).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.
